摘要
目的评价同步加量调强放疗（SIB－IMRT）联合尼妥珠单抗（泰欣生，h－R3）治疗局部晚期食管癌的近期疗效及安全性。
方法29例原发食管癌患者均采用同步加量调强放疗技术，处方剂量：PGTV/PGTVnd 60 Gy/2.4 Gy/25 F、PTV 50 Gy/2 Gy/25 F，每周泰欣生200 mg靶向治疗，同时观察近期疗效及急性不良反应。
结果29例患者均完成既定治疗方案，其中CR 14例（48.3%）、PR 13例（44.8%）、SD 1例（3.6%）、PD 1例（3.6%），有效率为93.1%。主要不良反应为Ⅰ～Ⅱ度放射性食管炎、骨髓抑制及放射性皮炎；尼妥珠单抗不良反应轻微，仅1例患者出现轻微皮疹。
结论同步加量调强放疗联合尼妥珠单抗治疗食管癌近期疗效较好，患者治疗耐受性良好，值得临床进一步研究。
To evaluate the short-term efficacy and toxicity of Nimotuzumab combined with simultaneous integrated boost intensity-modulated radiotherapy （SIB-IMRT） in the treatment of locally advanced esophageal carcinoma.
MethodsTwenty-nine patients with esophageal carcinoma were treated with SIB-IMRT. Planning gross target volume （PGTV） was given at a dose of 60 Gy/2.4 Gy/25 F and planning target volume （PTV） was given at a dose of 50 Gy/2 Gy/25 F. Nimotuzumab was given by intravenous drip at the dose of 200 mg, once a week before radiotherapy. Short-term efficacy and toxicity were evaluated in all patients.
ResultsAll patients completed the treatment successfully. Fourteen of them achieved a complete response （CR, 48.3%）, 13 had a partial response （PR, 44.8%）, 1 showed stable disease （SD, 3.6%）, and 1 showed progressive disease （PD, 3.6%）. The overall response rate （CR＋ PR） was 93.1%. Most adverse reactions were radioactive esophagitis, radioactive dermatitis and bone marrow suppression （grade 1-2）. Only 1 patient developed a slight skin rash.
ConclusionNimotuzumab combined with SIB-IMRT is a safe and effective modality for locally advanced esophageal cancer. The patient is well tolerated and worthy of further clinical study.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2016年第8期640-642,共3页
National Medical Journal of China
关键词
食管肿瘤
放射治疗剂量
尼妥珠单抗
近期疗效
Esophageal neoplasms
Radiotherapy dosage
Nimotuzumab
Short-term effect
